MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock from...
$2,688,552
(-3.92%↓ Y/Y)
Net cash provided by
financing activities
$2,622,427
(-35.26%↓ Y/Y)
Canceled cashflow
$66,125
Net decrease in cash
and cash...
-$668,647
(-121.07%↓ Y/Y)
Canceled cashflow
$2,622,427
Stock-based compensation
expense
$784,941
(45.84%↑ Y/Y)
Accounts payable
$133,634
(-26.79%↓ Y/Y)
Depreciation and
amortization
$61,556
(-77.02%↓ Y/Y)
Prepaid expenses and
other assets
-$17,660
(40.55%↑ Y/Y)
Payment on loans payable
$46,109
(-59.18%↓ Y/Y)
Principal repayments on
finance leases
$20,016
(-89.64%↓ Y/Y)
Net cash used in
operating activities
-$3,201,104
(25.36%↑ Y/Y)
Canceled cashflow
$997,791
Net cash used in
investing activities
-$89,970
(-40.11%↓ Y/Y)
Net loss
-$3,366,082
(49.92%↑ Y/Y)
Accrued expenses
-$614,354
(-75.19%↓ Y/Y)
Accounts and other
receivables
$209,587
(129.22%↑ Y/Y)
Inventory
$4,491
(-72.55%↓ Y/Y)
Operating lease
right-of-use asset
$4,381
(616.02%↑ Y/Y)
Purchase of property and
equipment
$89,970
(40.11%↑ Y/Y)
Back
Back
Cash Flow
bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc. (BIAF)
source: myfinsight.com